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Introduction: The available treatment options for euvolemic and hypervolemic hyponatremia 
are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these 
therapies are neither well tolerated nor totally effective, and many are associated with significant 
adverse effects. Vasopressin receptor antagonists, also known as vaptans, are a new class of agents 
that now offer an additional treatment option for hyponatremic patients. Conivaptan hydrochloride, 
a competitive antagonist of vasopressin V1a and V2 receptors, is the first agent in this class to be 
approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
Aims: This review critically assesses the evidence that support the use of conivaptan for the 
treatment of patients with euvolemic and hypervolemic hyponatremia.
Evidence review conclusion: Conivaptan is effective in raising serum sodium levels in a predict-
able and safe fashion in euvolemic and hypervolemic hyponatremic patients. Conivaptan provides 
the first molecularly targeted approach for correcting hyponatremia in hospitalized patients.
Keywords: Conivaptan hydrochloride, arginine vasopressin (AVP), hyponatremia, arginine 
vasopressin (AVP) receptor antagonist
Core evidence proof of concept summary table for conivaptan in hyponatremia
Outcome measure Emerging evidence
increased serum sodium levels 
in patients with euvolemic and 
hypervolemic hyponatremia.
Conivaptan is effective in raising serum sodium 
levels safely in 70%–80% of treated patients.
increased serum sodium levels 
in patients with hypovolemic 
hyponatremia.
Although effective at increasing serum sodium lev-
els in hypovolemic hyponatremia, use of conivaptan 
is contraindicated in such patients because of 
potential worsening of the volume depletion.
increased urine output due to 
aquaresis.
Dose-dependent increases in urine output 
and free water clearance are observed with 
increasing conivaptan doses, particularly in the 
first 24–48 hours of therapy.
Decreased requirement for fluid 
restriction.
The aquaresis associated with conivaptan use should 
decrease the severity of required fluid restriction; 
this has been documented with the selective V2r 
antagonist tolvaptan, but has not been studied with 
conivaptan.
improved QOL in patients with 
hyponatremia.
The long-term effect of conivaptan on QOL is 
under investigation; studies with the selective V2R 
antagonist tolvaptan have documented clinically 
relevant improvements in symptoms using the 
SF-12 patient self-assessment scale.
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Arginine vasopressin (AVP) is a nonpeptide that is 
synthesized in the neurohypophyseal magnocellular neurons 
of the supraoptic and paraventricular nuclei of the hypo-
thalamus. The synthesized AVP prohormone is packaged 
into neurosecretory granules and then transported down 
the supraopticohypophyseal tract to the posterior pituitary. 
During transport, pro-vasopressin is enzymatically cleaved 
into AVP, neurophysin, and a C-terminal glycopeptide. When 
release is stimulated, the circulating AVP binds to AVP V2 
receptors on the principal cells of the collecting duct of the 
kidney, activating a cyclic AMP-mediated signal transduc-
tion pathway that stimulates insertion of aquaporin-2 (AQP2) 
water channels into the apical membrane of the principal 
cells.1 The AQP2 channels lead to increased permeability 
of the renal collecting duct and reabsorption of water along 
osmotic gradients, thereby producing an antidiuresis. Under 
normal conditions, AVP secretion is closely regulated to 
maintain body water homeostasis. Thus, during conditions of 
hypertonicity or volume depletion, AVP secretion is stimu-
lated resulting in renal reabsorption of water and excretion 
of a concentrated urine by the kidneys. Conversely, during 
conditions of hypotonicity, AVP secretion is suppressed, 
leading to excretion of dilute urine by the kidneys.2
Hyponatremia is most often caused by inappropriately 
elevated plasma AVP levels, as epitomized by the syndrome 
of inappropriate secretion of antidiuretic hormone secretion 
(SIADH), which is caused by continued secretion of AVP 
despite plasma hypotonicity, leading to water retention and 
a dilutional decrease in serum sodium levels.3,4 The causes of 
SIADH are legion, including neoplasms, a variety of central 
nervous system and pulmonary disorders, and multiple drugs. 
Hyponatremia is the most common electrolyte disorder of 
hospitalized adult patients. When hyponatremia is defined 
as a serum sodium less than 135 mmol/L, incidences of 
6% to 22% have been reported.5,6 It is a serious electrolyte 
abnormality, which has been associated with high mortality 
among patients across a broad range of underlying conditions. 
Mortality rates in critically ill patients with symptomatic 
hyponatremia have been reported to be 60-fold higher than 
in patients without hyponatremia.7
The available treatment options for euvolemic and 
hypervolemic hyponatremia are limited, and consist of 
diuresis, fluid restriction, or hypertonic solutions. Most of 
these therapies are neither well tolerated nor totally effective, 
and many are associated with significant adverse effects.7 
The most recent approach to management of hyponatre-
mia is the development of a new class of medications that 
are antagonists to the vasopressin V2 receptor, which are 
called “vaptans” because of the suffix applied to the generic 
names of these agents. Vaptans correct hyponatremia by 
blocking the binding of AVP to V2 receptors in the kidney, 
thereby preventing AVP-mediated water reabsorption. 
Several AVP receptor antagonists have been developed for 
clinical use, for use in hyponatremia, including conivaptan 
(YM-087), lixivaptan (VPA-985), satavaptan (SR-121463), 
and tolvaptan (OPC-41060). All four of these agents increase 
urine volume and decrease urine osmolality, but have no 
appreciable effects on urine sodium or potassium excretion.8 
Conivaptan (Vaprisol®; Astellas Pharma US, Inc., Deerfield, 
IL. USA) was originally developed by Yamanouchi Pharma-
ceuticals (Tokyo, Japan), and is the first medication of this 
class to be approved by the US Food and Drug Administration 
(FDA) for treating euvolemic hyponatremia in a setting of 
SIADH, hypothyroidism, adrenal insufficiency, or pulmo-
nary disorders in hospitalized patients.9 Conivaptan later 
also received FDA-approved labeling for the treatment of 
(Continued)
Outcome measure Emerging evidence
improved respiratory symptoms in 
hyponatremic patients with Class iii 
or iV heart failure.
Conivaptan has not been shown to improve the 
severity of respiratory symptoms in patients with 
heart failure in short-term studies. Longer-term 
studies are in progress.
improved functional capacity in 
patients with heart failure.
The effect of conivaptan on functional capacity is 
under investigation.
Decreased length of hospital stay 
and resource utilization in hypona-
tremic patients.
Despite theoretical predicted improvements in 
length of hospital and iCU stay and corresponding 
decreases in resource utilization with use of 
conivaptan and other vaptans in hyponatremic 
patients, no study to date has been performed to 
assess this.
Abbreviations: ICU, intensive care unit; QOL, quality of life; V2R, vasopressin 2 receptor.Core Evidence 2009:4 85
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hypervolemic hyponatremia in hospitalized patients. This 
article critically reviews the evidence supporting the use of 
conivaptan in the treatment of euvolemic and hypervolemic 
hyponatremia in hospitalized patients.
Mechanism of action
Conivaptan is a nonpeptide antagonist with a high affinity 
for the human vasopressin receptor subtypes V1a and V2. 
The other vaptans mentioned earlier, lixivaptan, satavaptan, 
and tolvaptan, are selective V2 receptor antagonists, and do 
not have appreciable binding to the V1a receptors. Three 
subtypes of AVP receptors (AVPR) have been identified. 
The V1a receptor (V1aR) is ubiquitous and is located on 
the vascular smooth muscle cells, hepatocytes and platelets. 
Stimulation of V1aR results in vasoconstriction, glycoge-
nolysis, and platelet aggregation. The V1b receptor (V1bR) 
is found in the pituitary, where it mediates the release of 
adrenocorticotropic hormone (ACTH) in conjunction with 
corticotrophin-releasing hormone (CRH). The V2 receptor 
(V2R) is located primarily in the kidney, where it mediates 
antidiuresis.4 The major pharmacological effect of conivap-
tan in hyponatremia is accomplished by potent antagonism 
of V2R. As mentioned earlier, the V2R are functionally 
coupled to aquaporin-2 channels in the apical membrane of 
the collecting ducts of the kidney. Antagonism of V2R in 
the collecting duct of the kidney results in an increase in free 
water excretion or effective water clearance, net fluid loss, 
increased urine output, and decreased urine osmolality.10 
But unlike diuretic agents, conivaptan enhances free water 
excretion without significantly increasing renal excretion 
of sodium or potassium. Because of this basic difference, 
vaptans have been called “aquaretic” agents, ie, stimulating 
excretion of only water, to distinguish their renal effects from 
the increased solute and water excretion characteristically 
produced by diuretics.
Drug formulation and dosing
Conivaptan is available as an IV formulation in 4 mL 
ampoules containing 20 mg of conivaptan hydrochloride. 
A loading dose of 20 mg is administered through a large 
vein over 30 minutes, followed by a maintenance dose of 
20–40 mg per day for up to four days by continuous infusion. 
Peripheral intravenous infusion sites should be changed every 
24 hours to reduce common infusion site complications such 
as irritation and phlebitis resulting from the use of propylene 
glycol as a solvent in the ampules. A new formulation pre-
mixed in 100 ml infusion bags was approved by the FDA 
in October 2008, which should reduce complications from 
infusion site reactions since this formulation does not include 
propylene glycol. Close monitoring of serum sodium and 
volume status (every 4–6 hrs) is recommended with dose 
adjustments as necessary to achieve desired correction rates 
of the serum sodium concentration.9 Clinical trials of oral 
conivaptan have been reported at doses ranging from 20 to 
80 mg. However, further development of an oral formula-
tion was discontinued due to effects at the cytochrome P450 
isoenzyme 3A4 (CYP3A4), leading to potential prolongation 
of action of other drugs also metabolized by CYP3A4.
Pharmacokinetics
The pharmacokinetics of conivaptan have been studied in 
healthy and special populations using both the oral and the 
intravenous formulations. The peak diuretic effect of oral 
and intravenous conivaptan occurred between two to four 
hours,11–14 resulting in a seven-fold increase in urine flow 
rate and a decrease in urinary osmolality. The duration of 
aquaretic effect following single doses both orally and intra-
venously was 12 hours.11 Urine output returned to baseline 
value 12 hours following oral or intravenous administration 
of conivaptan. The effect of conivaptan on pulmonary capil-
lary wedge pressure (PCWP) in patients with advanced heart 
failure was sustained for approximately eight hours following 
the administration of intravenous conivaptan, and PCWP 
remained below baseline values even after 12 hours.13 The 
pharmacokinetics of 40 mg/day and 80 mg/day of intravenous 
and oral conivaptan were nonlinear, because conivaptan 
inhibits its own metabolism at CYP3A4.
Conivaptan is metabolized by the liver by CYP3A4, thus 
it can interact with other drugs that are also metabolized by 
CYP3A4. Because of this, conivaptan is contraindicated 
with the concurrent use of other potent CYP3A4 inhibitors 
such as ketoconazole, itraconazole, clarithromycin, ritona-
vir, and indinavir. Most of the drug is excreted in the feces 
(83%). The effects of hepatic or renal impairments on the 
pharmacokinetics of conivaptan have not been systemati-
cally evaluated.
Clinical efficacy
Hyponatremia
Conivaptan’s efficacy for the treatment of hyponatremia has 
been assessed in three randomized double-blinded, placebo-
controlled clinical trials and one open-label nonrandomized 
study. The three randomized studies include one pivotal 
study with intravenous conivaptan and two trials using 
oral conivaptan; the non-randomized study used intrave-
nous conivaptan. Phase III studies showed that conivaptan Core Evidence 2009:4 86
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reliably increases the serum sodium concentration, beginning 
as early as one to two hours after administration. Serum 
sodium increases by 2 to 4 mmol/L within 5 hours and by 
6 to 9 mmol/L within 24 hours after initiation of therapy at 
the 20-mg and 40-mg doses, respectively. In most patients, 
approximately 70%, the serum sodium normalized over a 
four-day continuous infusion, with the greatest increase in 
serum sodium occurring during the first 24 to 48 hours of 
treatment. The primary efficacy endpoint in these studies was 
the mean change in serum sodium over the duration of treat-
ment, as measured by the area under the serum sodium effect 
curve (AUC), corrected for baseline serum sodium.15–17
In the pivotal phase III trial conducted with IV conivaptan,17 
84 patients with euvolemic or hypervolemic hyponatremia 
(serum sodium 115–130 mEq/L) were randomized to receive 
conivaptan 40 mg/day, 80 mg/day or placebo for four days. The 
continuous infusion of conivaptan was preceded by a 20 mg 
intravenous loading dose. Of 84 total patients included in the 
intention-to-treat analysis, 66 completed treatment. Both doses 
of conivaptan were associated with significant improvements 
in serum sodium compared to placebo as measured by both the 
primary and secondary efficacy endpoints (Table 1). All patients 
also received standard care treatments for hyponatremia, which 
primarily consisted of fluid restriction. This was not a strict fluid 
restriction, ie, 2 liters/day, because the primary goal was to 
prevent the patients on placebo from worsening, rather than as 
an active treatment for hyponatremia. A planned subgroup anal-
ysis of this trial was performed to evaluate the efficacy of intra-
venous conivaptan in patients with euvolemic hyponatremia.18 
Fifty-six of the 84 patients analyzed in the trial were euvolemic. 
Conivaptan 40 and 80 mg/day effectively raised mean serum 
sodium on the first day of treatment. The mean increase in 
serum sodium with conivaptan remained significantly greater 
than that with placebo at the end of the four-day treatment 
period. The placebo group did not demonstrate any significant 
changes in serum sodium concentration (Figure 1).
Of the two oral conivaptan trials, one has been published.16 
The efficacy of oral conivaptan was evaluated in 74 euvolemic 
and hypervolemic hyponatremic patients who were random-
ized to receive oral conivaptan 40 mg/day, 80 mg/day, or 
placebo, all given in two divided doses/day for five days. 
Both doses of conivaptan were associated with significant 
dose-dependent improvements in serum sodium compared to 
placebo (Table 2). Results from the second oral conivaptan 
study are available in abstract form only.15 The study, similar 
to the other oral conivaptan study, included 83 patients with 
euvolemic and hypovolemic hyponatremia, and revealed the 
same dose-dependent increase in serum sodium concentrations 
(Table 2).
Results from the open-label multicenter trial using intrave-
nous conivaptan were presented at the Annual Meeting of the 
Endocrine Society in June 2008.19 The study was conducted 
from February 2004 to June 2005, and included 251 hospital-
ized patients with euvolemic and hypervolemic hyponatremia 
to assess the efficacy and safety of intravenous conivaptan 
20 and 40 mg/day for four days and for up to 30 days after 
cessation of therapy. The most common underlying illness 
associated with hyponatremia was SIADH (43% of patients). 
Table 1 Efficacy results from the pivotal phase III intravenous conivaptan trial16
  Placebo (n = 29) 40 mg/day (n = 29) 80 mg/day (n = 26)
Baseline serum Na (mEq/L) 124.3 ± 4 123.3 ± 4.7 124.8 ± 3.4
Primary efficacy endpoint
Change from baseline serum Na AUC to day 4 
(LS mean ± SE, in mEq/L-hr)
12.9 ± 61.2 490.9* ± 56.8 716.6* ± 60.5
Secondary efficacy endpoints
Median time to serum Na 4 mEq/L increase 
over baseline [hrs (95% Ci)]
NE 23.7* (10–24) 23.4* (6–24)
Mean total time serum Na 4 mEq/L over 
baseline (LS mean in hrs ± SE)
14.2 5.3 53.2* ± 5.2 72.7* ± 5.4
Mean change in serum Na from baseline  
to end of day 4 [LS mean in mEq/L ± SE  
(# of evaluable patients)]
2 ± 0.82 (n = 25) 6.8* ± 0.81  
(n = 24)
9* ± 0.8 (n = 24)
Number of patients with 6 mEq/L increase 
in serum Na or increase to normal serum Na 
(135 mEq/L) (%)
6 (21) 20 (69)* 23 (89)*
Notes: *Significant vs placebo.
Abbreviations: AUC, area under the curve; LS, least squares; NE, not estimable.Core Evidence 2009:4 87
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Conivaptan was associated with significant increases in 
serum sodium concentration that were sustained throughout 
the study. At the cessation of active therapy, the mean serum 
sodium increased by 9.4 and 8.8 mEq/L in patients given 
conivaptan 20 and 40 mg/day, respectively. The response 
did not appear to differ significantly among patients given 
20 or 40 mg/day. Very interestingly, the increases in serum 
sodium over baseline achieved through the end of treatment 
persisted through days 11 and 34 after initiation of aquaretic 
therapy even though the duration of active treatment was only 
four days. The reason for the persistence of the correction is 
unknown, but it suggests that limited infusions of conivaptan 
may be sufficient to improve hyponatremia not only during 
active treatment, but also for longer periods of time in patients 
who have improvement in their underlying comorbidities 
responsible for the hyponatremia.
Heart failure
Although conivaptan has been evaluated extensively in 
patients with congestive heart failure (CHF), efficacy has not 
been established other than for correction of hyponatremia; 
thus, conivaptan is not indicated for primary treatment of CHF 
at this time. Vasopressin levels are often elevated in patients 
with heart failure and left ventricular (LV) dysfunction,20 
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and they are clearly associated with adverse cardiovascular 
outcomes in the setting of LV dysfunction after myocardial 
infarction.21 These data suggest that vasopressin may contrib-
ute to the circulatory response in patients with heart failure, 
and may also play a role in the development and progression 
of heart failure. Combined V1aR/V2R antagonism with 
conivaptan therefore does offer a theoretical benefit in CHF. 
If systemic hemodynamic improvement occurs with V1aR 
antagonism, renal hemodynamics would improve as well with 
V2R antagonism, leading to a greater clinical benefit.
The hemodynamic effects of conivaptan were evaluated 
in a prospective, randomized, double-blind study of 142 patients 
with New York Heart Association (NYHA) Class III or IV 
heart failure of at least three months duration.13 Subjects 
were randomized to receive a single dose of intravenous (IV) 
conivaptan (10, 20, or 40 mg) or placebo, administered over 
30 minutes. Conivaptan produced favorable hemodynamic 
changes in patients with advanced heart failure, without affect-
ing blood pressure or heart rate. Pulmonary capillary wedge 
pressure and right atrial pressure were significantly reduced in 
the conivaptan 20 mg and 40 mg groups at three to six hours 
post-dose as compared with the placebo groups. Urine output 
was significantly higher in the conivaptan-treated patients 
as compared with placebo, and dose-dependent increases in 
urine output were observed with increasing conivaptan doses 
(p  0.001). Despite conivaptan’s properties as a V1aR antago-
nist, it had no significant effects on systolic blood pressure and 
pulse rate. No statistically significant changes in cardiac index, 
mean arterial pressure, pulmonary artery pressure, systemic or 
pulmonary vascular resistance were observed among the treat-
ment groups. Serum osmolality, serum sodium, and potassium 
levels were similar among conivaptan and placebo groups. Of 
note, the patients were fluid-restricted to 250 mL every two 
hours during the 12-hour study periods and background diuret-
ics and other medications were held during the study period. It 
should be noted that this study only examined the acute altera-
tions in hemodynamics following a single intravenous dose of 
conivaptan. Despite the encouraging results of this study, other 
pilot and phase II studies have not shown benefits in clinical 
outcomes with longer term conivaptan use.
In a double-blind, dose-ranging pilot study,22 162 hospital-
ized patients with NYHA Class III or IV heart failure were 
randomized to receive conivaptan 20 mg by intravenous bolus 
followed by continuous infusion of 40 mg/day, 80 mg/day, 
120 mg/day, or placebo for two days. Efficacy endpoints 
included change in respiratory symptoms, urine output and 
weight. Ten patients in the conivaptan groups and one in the 
placebo group discontinued the drug due to adverse events. 
Significant increases in urine output and changes in body 
weight were observed with all doses of conivaptan compared 
to placebo, but conivaptan did not improve the severity of 
respiratory symptoms.
A Dose evaluation of Vasopressin ANtagonist in CHF 
patients undergoing Exercise (ADVANCE) was a multi-
center, double-blind, placebo-controlled, randomized trial 
designed to investigate the effect of conivaptan on functional 
Table 2 Efficacy results from oral conivaptan trials14,15
Ghali et al Gross et al
Placebo
(n = 23)
40 mg/day
(n = 24)
80 mg/day
(n = 27)
Placebo
(n = 30)
40 mg/day
(n = 27)
80 mg/day
(n = 26)
Baseline serum Na (mEq/L) 123.4 ± 4.1 125.3 ± 3.5 125.4 ± 4 125.6 ± 3.9 125.1 ± 5.1 125.6 ± 3.6
Primary efficacy endpoint
Change from baseline serum Na AUC 
to day 5 (LS mean ± SE, in mEq/L-hr)
309.2 ± 94.8 621.3* ± 89 836.2* ± 87.8 87.5 ± 80.8 634.2* ± 84.2 952.7* ± 85.7
Secondary efficacy endpoints
Median time to serum Na 4 mEq/L 
increase over baseline [hrs (95% Ci)]
71.7 (49-NE) 27.5* (12–47) 12.1* (11–28) NE 23.5* (12–24) 8.7* (6–24)
Mean total time serum Na 4 mEq/L 
over baseline (LS mean in hrs ± SE)
46.5 ± 9 69.8* ± 8.5 88.8* ± 8.4 n/a n/a n/a
Mean change in serum Na from baseline 
to end of day 4 [LS mean in mEq/L ± SE]
3.4 ± 1.1 6.4 ± 1 8.2* ± 1 1 ± 0.9 6.8* ± 0.9 8.8* ± 0.9
Number of patients with 6 mEq/L 
increase in serum Na or increase to 
normal serum Na (135 mEq/L) (%)
11 (48) 17 (71) 22 (82)* 6 (20) 18 (67)* 23 (89)*
Notes: Bioavailability of oral conivaptan is ∼30%; *Significant vs placebo.
Abbreviations: NE, not estimable; LS, least squares; n/a, not available.Core Evidence 2009:4 89
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capacity in patients with heart failure.23 The study enrolled 
345 patients with NYHA class II to IV symptoms who were 
being treated with standard pharmacotherapy for heart failure. 
Three oral doses of conivaptan were compared with placebo 
for 12 weeks. Currently, only the methodology of this trial 
has been published, but additional results are anticipated in 
the future.
Tolerability
Conivaptan was generally well tolerated with the majority 
of reactions being mild. The majority of adverse events were 
infusion site reactions during intravenous administration, 
likely as a result of propylene glycol, which is irritating to 
veins. These reactions occurred in over 50% of conivaptan 
patients compared with 2% of placebo-treated patients dur-
ing clinical trials (Table 3). A new formulation pre-mixed in 
100 ml infusion bags was approved by the FDA in October 
2008, and should reduce infusion site complications since this 
formulation does not include propylene glycol. Infusion site 
reactions were the most common reason for discontinuation 
during clinical trials. Although most infusion site complica-
tions were minor, including local inflammation, phlebitis, and 
pain at the infusion site, some serious infusion site reactions 
did occur.
Other side effects in decreasing order included headaches, 
hypokalemia, thirst, vomiting, polyuria, peripheral edema, 
diarrhea, and orthostatic hypotension. Orthostatic hypotension 
generally occurred on days 1 and 2 of therapy, likely because 
of volume depletion from induced aquaresis. Although V1aR 
antagonism on vascular smooth muscle could contribute to 
hypotension as well, this is less likely because: (1) AVP is 
not necessary for blood pressure homeostasis,8 and (2) the 
orthostatic hypotension was mild, short lived, and did not 
result in withdrawal of patients from the studies.
Another safety concern that occurred in approximately 9% 
of the subjects during clinical trials was a too-rapid correc-
tion of serum sodium concentration with the administration 
of conivaptan.9 Overly rapid correction of severe hypona-
tremia can produce pontine and extrapontine myelinolysis, 
also called osmotic demyelination syndrome (ODS), a brain 
demyelinating disease that can cause substantial neurological 
morbidity and mortality.24 However, no cases of ODS were 
noted in any of the clinical trials, nor have been reported 
with subsequent clinical use of conivaptan since 2006. This 
is likely the result of using titrated doses of conivaptan with 
careful monitoring of the serum sodium concentrations during 
the active phase of correction, thereby achieving a controlled 
and limited correction of hyponatremia.4
Review of data from patients with adverse effects of 
hypokalemia revealed that the occurrence of a low serum 
potassium 3.3 mEq/L (the protocol-defined low threshold 
for hypokalemia, normal reference range: 3.5–5.0 mEq/L) at 
the end of days 2 and 4 was not nearly as high as the reported 
occurrence of hypokalemia adverse events. Overall changes 
from baseline in serum potassium during the four-day treat-
ment period were mild, and did not reach a level of clinical 
significance.
Clinical indications
Hyponatremia
Conivaptan is currently indicated for the treatment of 
euvolemic hyponatremia as a result of SIADH, pulmonary 
disorders, hypothyroidism or adrenal insufficiency, and for 
the treatment of hypervolemic hyponatremia. A panel of 
experts in hyponatremia evaluated the situations in which 
aquaretic agents should be considered for therapy.18 In hypo-
volemic hyponatremia, induced aquaresis would aggravate 
the underlying volume depletion. Consequently, conivaptan 
and all other vaptans are contraindicated in hypovolemic 
hyponatremia. For euvolemic hyponatremia, aquaretic agents 
will likely become a mainstay of treatment. However, careful 
clinical assessment of the patient and an accurate diagnosis 
of euvolemic hyponatremia are necessary before therapy is 
prescribed. In hypervolemic hyponatremia, antagonism of 
V2R represents the best approach to treating hyponatremia 
in most edema-forming states such as congestive heart failure 
and cirrhosis, because excess AVP is the most important 
pathophysiological factor involved in the pathogenesis of 
hyponatremia under these conditions, and because therapies 
employing administration of sodium chloride are generally 
contraindicated in such patients.
Potential therapeutic indications 
for conivaptan and similar agents
Congestive heart failure
Patients with CHF often do not correct hypo-osmolar 
hyponatremia with conventional diuretic therapy. However, 
reversing impaired free water excretion with conivaptan 
normalizes dilutional hyponatremia in congestive heart 
failure patients.4,17 Conivaptan and other V2R antagonists 
will likely prove to be superior to conventional diuretics 
in this setting, since they can induce free water diuresis 
without an accompanying solute diuresis. Tolvaptan, an oral 
V2R antagonist, has been assessed in several trials for the 
management of acute and chronic heart failure. The Acute Core Evidence 2009:4 90
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Table 3 Adverse reactions occurring in 5% of patients or healthy volunteers during the pivotal phase iii trial8
Side effect Placebo (n = 69) 20 mg (n = 37) 40 mga (n = 315)
N (%) N (%) N (%)
Blood and lymphatic system disorders
  Anemia NOS 2 (3%) 2 (5%) 18 (6%)
Cardiac disorders
  Atrial fibrillation 0 (0%) 2 (5%) 7 (2%)
Gastrointestinal disorders
  Constipation 2 (3%) 3 (8%) 20 (6%)
  Diarrhea NOS 0 (0%) 0 (0%) 23 (7%)
  Nausea 3 (4%) 1 (3%) 17 (5%)
  Vomiting NOS 0 (0%) 2 (5%) 23 (7%)
General disorders and administration 
site conditions
  Edema peripheral 1 (1%) 1 (3%) 24 (8%)
  infusion site erythema 0 (0%) 0 (0%) 18 (6%)
  infusion site pain 1 (1%) 0 (0%) 16 (5%)
  infusion site phlebitis 1 (1%) 19 (51%) 102 (32%)
  infusion site reaction 0 (0%) 8 (22%) 61 (19%)
  Pyrexia 0 (0%) 4 (11%) 15 (5%)
  Thirst 1 (1%) 1 (3%) 19 (6%)
infections
  Pneumonia NOS 0 (0%) 2 (5%) 7 (2%)
  Urinary tract infection NOS 2 (3%) 2 (5%) 14 (4%)
injury, poisoning and procedural 
complications
  Post-procedural diarrhea 0 (0%) 2 (5%) 0 (0%)
investigations
  ECG ST segment depression 0 (0%) 2 (5%) 0 (0%)
Metabolism and nutrition disorders
  Hypokalemia 2 (3%) 8 (22%) 30 (10%)
  Hypomagnesemia 0 (0%) 2 (5%) 6 (2%)
  Hyponatremia 1 (1%) 3 (8%) 20 (6%)
Nervous system disorders
  Headache 2 (3%) 3 (8%) 32 (10%)
Psychiatric disorders
  Confusional state 2 (3%) 0 (0%) 16 (5%)
  insomnia 0 (0%) 2 (5%) 12 (4%)
respiratory, thoracic and mediastinal 
disorders
  Pharyngolaryngeal pain 3 (4%) 2 (5%) 3 (1%)
Skin and subcutaneous tissue disorders
  Pruritus 0 (0%) 2 (5%) 2 (1%)
Vascular disorders
  Hypertension NOS 0 (0%) 3 (8%) 20 (6%)
  Hypotension NOS 2 (3%) 3 (8%) 16 (5%)
  Orthostatic hypotension 0 (0%) 5 (14%) 18 (6%)
Notes: aAlthough an intravenous dose of conivaptan 80 mg/day was also studied, it was associated with a higher incidence of infusion site reactions and a higher rate of 
discontinuation due to adverse events than the 40 mg/day dose.   The maximum FDA-approved daily intravenous dose of conivaptan (following the loading dose) is 40 mg/day.
Abbreviations: ECG, electrocardiogram; NOS, not otherwise specified.Core Evidence 2009:4 91
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and Chronic Therapeutic Impact of Vasopressin antagonist 
in Congestive Heart Failure (ACTIV in CHF) trial was a 
multicenter, randomized controlled trial with 319 patients 
with acute exacerbation of CHF.25 21.3% of the patients had 
hyponatremia (serum sodium 136 mEq/L) at randomiza-
tion. Patients were randomized to receive one of three doses 
of oral tolvaptan or placebo for up to 60 days in addition 
to standard CHF therapy. All tolvaptan groups had signifi-
cant reductions in body weight compared with the placebo 
group and had significantly higher urine volumes than the 
placebo group. These differences persisted throughout the 
hospital stay. A large phase III multi-center trial, Efficacy 
of Vasopressin antagonist in hEart failuRE outcome Study 
with Tolvaptan (EVEREST), compared the short-term 
and long-term administration of tolvaptan with placebo in 
4133 patients admitted with worsening heart failure.26,27 In the 
short-term study, tolvaptan patients lost more weight on day 1 
and day 7 or on discharge. More patients receiving tolvaptan 
reported improvement in dyspnea on day 1 and reduction in 
edema on day 7, whereas improvement in general clinical 
status did not differ between groups.25 However in the long-
term study, with a median follow-up of 9.9 months, tolvaptan 
had no effect on long-term mortality or heart failure-related 
morbidity.27 Within the limitations inherent in this study, the 
long-standing association between adverse outcomes and 
hyponatremia in patients with CHF does not appear to be 
due to adverse effects of the hyponatremia itself.28
Cirrhosis
Patients with cirrhosis, intractable ascites, and peripheral 
edema are often ineffectively treated with aldosterone antago-
nists and beta-blockers, but it is currently not advisable to use 
conivaptan in patients with cirrhosis because V1aR inhibition 
may block the vasoconstrictive effects of AVP in the portal 
and splanchnic circulation, possibly increasing portal blood 
flow. However, decreases in portal hypertension may offset 
this effect. Consequently, the net effect of conivaptan on the 
risk of precipitating esophageal variceal bleeding is unknown. 
Theoretically, selective V2R antagonists should not entail 
adverse effects on portal hemodynamics, but their safety 
in cirrhosis remains to be ascertained. One of the other oral 
V2R antagonists, lixivaptan, has been studied in patients with 
cirrhosis. One randomized controlled trial of 44 hospitalized 
patients with stable hyponatremia that included 33 patients 
with cirrhosis showed that a seven-day course of lixivaptan 
was well tolerated and increased free water clearance, urine 
output and serum sodium concentrations in a dose-dependent 
manner.29 Another study of 60 patients with cirrhosis showed 
an increase in serum sodium concentration after seven days of 
treatment to a mean of 132 mEq/L compared with 126 mEq/L 
in the placebo group.30 Lixivaptan had no significant effects 
on blood pressure or heart rate.
Long-term treatment of hyponatremia
Most placebo-controlled studies using AVPR antagonists to 
treat hyponatremia have been of relatively short duration. 
However, recent data from two multicenter 30-day placebo-
controlled trials of tolvaptan resulted in sustained correction 
of hyponatremia and improved cognitive function.31 Another 
study using satavaptan, an oral V2R antagonist, began as a 
five-day randomized, placebo-controlled trial in patients with 
SIADH and continued as an open-label trial which showed 
continued efficacy and good tolerance for up to 12 months 
of treatment.32 Under a fluid restriction of 1500 mL/day, 
mean serum sodium levels remained within the normal range 
during the open-label period. Long-term response rates to oral 
conivaptan and other AVPR antagonists, and whether correc-
tion of chronic hyponatremia results in improved functional 
status and quality of life, will require additional studies.
Conclusions
Conivaptan, along with the other AVPR antagonists, produce 
an aquaretic effect by blocking the activity of endogenous 
AVP at the V2R, which improves dilutional hyponatremia. 
The current data indicate that these agents are highly effec-
tive in producing a safe and predictable aquaresis, thereby 
increasing serum sodium levels in hyponatremic patients. 
Conivaptan is the first AVPR antagonist to receive FDA 
approval, specifically for IV administration to hospitalized 
patients with euvolemic or hypervolemic hyponatremia. 
Several investigational oral V2R-selective AVPR antagonists 
are in late-stage clinical trials and hold promise for long-term 
therapy of chronic hyponatremia. The advent of these agents 
represents a significant achievement for the management of 
hyponatremia. However, the safe use of conivaptan and other 
aquaretics will require avoidance of their use in hypovolemic 
patients and caution with regard to the correction rate of 
hyponatremia. Clinicians must also be aware of drug interac-
tions, particularly drugs that are metabolized by cytochrome 
CYP3A4. Close monitoring of serum sodium and volume 
status is necessary in patients receiving conivaptan.
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